Go to BioCentury homepage
Print this Print this

Welcome to BCIQ: BioCentury Online Intelligence.
Free access to this and other abridged company profiles is provided to all subscribers to SciBX: Science-Business eXchange.

Please explore the profile and if you wish to find out more about BCIQ - please Click Here

Nippon Shinyaku Co. Ltd.

Print preview Print preview

(Tokyo:4516; Osaka:4516)

Collapse Summary

General Information

 Location Kyoto, Japan
 Region
 Country Japan
 Business Category Pharmaceuticals
 Year Founded 1919
 Website www.nippon-shinyaku.co.jp
 Development Status Market (drug) (04/26/2007)

Archive Items are loading

Collapse Summary

Pipeline Information

Disease CategoryResearchPhase IPhase I/IIPhase IIPhase II/IIIPhase IIIRegistrationApprovedMarketed
Cancer

-

1

-

-

-

-

-

1

1

Cardiovascular

-

-

-

1

-

-

-

-

-

Inflammation

-

-

-

1

-

-

-

-

1

Neurology

-

-

-

1

-

-

1

-

-

Total

-

1

-

3

-

-

1

1

2


Pipeline Details - Originated and out-licensed products (5 records)

Product Names

Disease Category

Standard Indication

Partners

Milestones

Latest Stage of Development

ACT-293987 (Compound #), NS-304 (Compound #)

Cardiovascular

Hypertension

Actelion Ltd.

 

Phase II

INNO-406 (Former compound #), NS-187 (Former compound #), Bafetinib (Other)

Cancer

Chronic myelogenous leukemia (CML)

CytRx Corp.

Phase I data (3Q09)

Phase I


Pipeline Details - In-licensed products (3 records)

Product NamesDisease CategoryStandard IndicationIn-licensed fromMilestonesLatest Stage of DevelopmentRights

Bay u 3405 (Compound #), ramatroban (Generic), Baynas (Informal)

Inflammation

Rhinitis

Bayer AG

 

Marketed

Commercialization

Trisenox (Brand), arsenic trioxide (Chemical), ATO (Chemical), Trisenox (Informal)

Cancer

Acute promyelocytic leukemia (APL)

Cephalon Inc.

 

Marketed

Development